Table 4.
A summary of clinical studies for pretreatment EPID based PSQA.
| System | Author | Tests performed | Results |
|---|---|---|---|
| Dosimetry Check (RadCalc EPID) | Chendi et al. 2021 | 20 FFF plans, compared to Octavius phantom measurement and TPS calculation (in-patient CT) | Poor correlation in gamma-pass rates |
| Epiqa | Fogliata et al. 2011 | 295 patient VMAT plans, 5 centers | Mean gamma 97.1±2.4% at 3%,3mm |
| Epiqa | Nicolini et al. 2013 | 74 arcs VMAT FFF | Similar to non FFF if > 150 cm EPID distance |
| Portal Dosimetry | Howell et al. 2008 | 152 patient IMRT plans (1152 fields) | Mean gamma value tolerances established |
| Portal Dosimetry | Iori et al. 2010 | 23 arcs VMAT | Same results as IMRT but using external EPID fixation device |
| Portal Dosimetry | Bailey et al. 2012 | Prostate, head neck, breast IMRT (126 fields) | Off axis breast tangents lower results, may not adequately model off axis |
| Portal Dosimetry | Ballangrud et al. 2018 | 40 multitarget SRS deliveries | γ pass rate of greater than 95% for most fields at 3%/2 mm criteria with a 10% threshold |
| Portal Dosimetry | Covington et al. 2019 | 36 plans single-target SRS VMAT QA for at 10FFF energy | composite EPID image of the two arcs 3%/2 mm criteria with 10% threshold a 100% pass rate |
| Portal Dosimetry | Koo et al. 2020 | 200 breast IMRT plans | Average gamma passing rate of 98·4 ± 4·3 for 2%/2 mm symmetric plans and 89·7 ± 9·5 for 2%/2 mm asymmetric plans |